LivingGLP1
Study S000885

Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT02303730
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
NONE
Status
COMPLETED
Enrollment
76
Start
2015-03
Primary completion
2017-11
Lead sponsor
Fudan University
Conditions
Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease
Interventions
DRUG:Exenatide; DRUG:insulin glargine
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in liver fat content（%） measured by MRS [baseline and 24 weeks]

Linked records (9)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0020329Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
Liu L, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2023Randomized trialPMID 37524110DOIcites ClinicalTrials.gov:NCT02303730; registry reference DERIVED:37524110
R0026331Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).
Xu W, Journal of internal medicine
2015Randomized trialPMID 25039675DOIregistry reference BACKGROUND:25039675
R0026284Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Shao N, Diabetes/metabolism research and reviews
2014Randomized trialPMID 24823873DOIregistry reference BACKGROUND:24823873
R0014056Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Cuthbertson DJ, PloS one
2012OtherPMID 23236362DOIregistry reference BACKGROUND:23236362
R0017141GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.
Sharma S, PloS one
2011PreclinicalPMID 21957486DOIregistry reference BACKGROUND:21957486
R0024740Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P, Obesity (Silver Spring, Md.)
2011OtherPMID 21660077DOIregistry reference BACKGROUND:21660077
R0023473Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
Gupta NA, Hepatology (Baltimore, Md.)
2010PreclinicalPMID 20225248DOIregistry reference BACKGROUND:20225248
R0024803Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
Okerson T, American journal of hypertension
2010Randomized trialPMID 20019672DOIregistry reference BACKGROUND:20019672
R0027332Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
Kenny PR, The American journal of gastroenterology
2010Case reportPMID 21131943DOIregistry reference BACKGROUND:21131943